Services / US generics market entry
Enter the US generics market
Market data tells you what to make. We find the US company that will buy it, and stay on your side until the supply contract is signed.
- First sheet free, in two working days
- Paid mostly from the revenue you win
- No fee for US buyers
One molecule’s US record, on one page
Sample sheet from public data, November 2026
Symbicort
Budesonide and formoterol, metered inhalation aerosol
- Orange Book patents and exclusivities
- None listed on 9 Oct 20261
- Approved generic applications
- 21
- Authorized generic, sold under the brand’s own approval
- Listed by AstraZeneca and 2 other labelers2
- First Paragraph IV patent challenge
- June 20183
- Medicare Part D spending, 2024
- US$597.8 million4
An approved count is not a competitor count: generic applications under review are confidential. An NDC listing is the labeler’s own filing, not an approval. FDA’s Paragraph IV list gives a last qualifying patent expiring 16 Oct 20283, and a challenge is not a win or an approval. Spending is CMS’s row “Symbicort”, before rebates and Medicare only, linked to the drug by PhaseFolio through its FDA trade name.
A report tells you what to make. We find who buys it.
Your portfolio team already knows the market. What it rarely has is a US buyer asking for your product, and someone on your side while the terms are agreed.
We start from the buyer
We ask US generic companies, distributors and hospital buyers which molecules they need a second source for, then bring those requests to manufacturers who can make them.
We earn when you do
Most of our fee is a share of the revenue you win. We only spend time on products a buyer will take, and we stay with you through documents, samples and follow-ups until the contract is signed.
The public US record, on one page
FDA approvals, patent challenges, authorized generics, shortages and Medicare spending sit with different agencies under different names. We link them to the same drug and cite every figure. Your first sheet is free.
Buying in the US? Get a second source.
Name the molecule. We bring you manufacturers whose FDA approvals and product listings are on a molecule sheet both sides read from. It costs you nothing: the manufacturer pays us, and we tell you so up front.
How it works
1
Free molecule sheet
Name one product. Its US record in two working days.
2
Opportunity scan
Your whole portfolio against the US market. A fixed fee, credited to your commission.
3
Introductions
Meetings with US buyers who need your product.
4
Representation
We stay on it until the supply contract is signed.
Get your free molecule sheet
Email us a product. We send its US record within two working days and show you where it fits.
What to send
- Your company and the country you make in
- The products or molecules you make, or want to make
- Finished doses, active ingredients, or both
- Or, for a US buyer: the molecule you need a second source for
We never share your product list with a competing manufacturer. Privacy policy
Molecule sheets draw on FDA’s Orange Book, Paragraph IV list, National Drug Code Directory and drug shortage data (through openFDA), NLM’s RxNorm, and CMS’s Medicare Part D and Part B spending by drug. Each figure names its source and date. A missing patent, challenge or shortage record never means there is none. Medicare spending is before rebates and covers Medicare only.
This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product. FDA and CMS do not endorse PhaseFolio. Not legal, medical or investment advice.